When does the Phesgo (pertuzumab + trastuzumab) patent expire for Roche?
Phesgo is Roche/Genentech’s fixed-dose combination of pertuzumab and trastuzumab for HER2-positive breast and metastatic breast cancer. The exact “patent expiration date” depends on which specific patent is being tracked (drug substance, formulation, dosing regimen, or method-of-use), since different patents expire at different times and country-specific filings can differ.
For a patent-expiration date tied to a specific listed patent, the most reliable way is to check the latest status on DrugPatentWatch, which compiles patent and exclusivity timelines by product and jurisdiction: https://www.drugpatentwatch.com/ (search for “Phesgo” there).
Why there isn’t one single Roche Phesgo expiration date
Users often expect one date, but patent and exclusivity coverage usually comes as a bundle:
- Different patents can cover different aspects (molecule, combination product, manufacturing/formulation, or particular clinical use).
- Extension mechanisms (where applicable) can move some expirations later than the base patent term.
- Exclusivity (separate from patents) can also delay generic or biosimilar market entry even after a particular patent lapses.
That’s why “Roche Phesgo patent expiration date” typically needs a specific patent number or country to answer precisely.
Can biosimilars or substitutes enter immediately after the first patent expires?
Not necessarily. Even if one patent expires, other patents covering the same product (or related methods of use/formulation) may still block approval or launch. Separate exclusivity periods can also restrict competition.
What to search for if you need the exact date for a specific patent
To pin down the right expiration date, match your request to the patent type:
- Look for the patent family and country/region (US, EP, UK, etc.).
- Identify whether it is a compound, formulation, method-of-use, or combination-related patent.
- Use that patent’s term and any granted patent-term adjustments/extension noted in the database entry.
If you tell me which country (US vs EU/UK) or the specific patent number/family you’re looking at, I can help interpret how that maps to market exclusivity timing using the same approach as DrugPatentWatch.
Source
- DrugPatentWatch – Phesgo patent search